Thibault Boutherin
Stock Analyst at Morgan Stanley
(3.55)
# 2,205
Out of 4,520 analysts
161
Total ratings
61.8%
Success rate
6.8%
Average return
Main Sectors:
Stocks Rated by Thibault Boutherin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Maintained: Buy | CHF 135.00 | CHF 125.00 | +8.00% | 13 | Jun 25, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 270.00 → kr 250.00 | kr 332.79 | -24.88% | 6 | May 7, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Hold | CHF 155.00 → CHF 160.00 | CHF 172.50 | -7.25% | 9 | Apr 27, 2026 | |
| NVS Novartis AG | Maintained: Buy | $143 → $170 | $153.76 | +10.56% | 3 | Mar 26, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €40.00 → €53.00 | €48.46 | +9.37% | 5 | Mar 11, 2026 | |
| BME: GRF Grifols, S.A. | Downgraded: Hold | €12.00 → €11.00 | €9.08 | +21.17% | 7 | Mar 10, 2026 | |
| NVO Novo Nordisk | Upgraded: Hold | $42 → $40 | $50.32 | -20.51% | 5 | Mar 3, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $28 → $36 | $40.54 | -11.20% | 11 | Dec 3, 2025 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 → €135.00 | €136.30 | -0.95% | 5 | Dec 3, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 650.00 | CHF 567.80 | +14.48% | 10 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $10 | $3.46 | +189.02% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 38.00 → CHF 50.00 | CHF 65.74 | -23.94% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €300.00 | €243.40 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €250.00 | €185.70 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €715.00 | €750.50 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 2,100p → 2,400p | 1,561p | n/a | 15 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 | $1.96 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €12.00 | €3.44 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 912p | 1,288p | n/a | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 | €161.40 | n/a | 18 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $37 → $40 | $81.15 | n/a | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | CHF 4.00 → CHF 1.00 | CHF 5.90 | n/a | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €0.88 → €105.00 | €235.60 | n/a | 12 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 | $7.27 | n/a | 4 | Dec 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €11.50 → €11.00 | €10.68 | n/a | 5 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $32.03 | n/a | 2 | Oct 4, 2023 |
Novartis AG
Jun 25, 2026
Maintained: Buy
Price Target: CHF 135.00
Current: CHF 125.00
Upside: +8.00%
Novo Nordisk A/S
May 7, 2026
Maintained: Hold
Price Target: kr 270.00 → kr 250.00
Current: kr 332.79
Upside: -24.88%
Galderma Group AG
Apr 27, 2026
Maintained: Hold
Price Target: CHF 155.00 → CHF 160.00
Current: CHF 172.50
Upside: -7.25%
Novartis AG
Mar 26, 2026
Maintained: Buy
Price Target: $143 → $170
Current: $153.76
Upside: +10.56%
Bayer Aktiengesellschaft
Mar 11, 2026
Maintained: Buy
Price Target: €40.00 → €53.00
Current: €48.46
Upside: +9.37%
Grifols, S.A.
Mar 10, 2026
Downgraded: Hold
Price Target: €12.00 → €11.00
Current: €9.08
Upside: +21.17%
Novo Nordisk
Mar 3, 2026
Upgraded: Hold
Price Target: $42 → $40
Current: $50.32
Upside: -20.51%
Indivior Pharmaceuticals
Dec 3, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $40.54
Upside: -11.20%
Merck KGaA
Dec 3, 2025
Maintained: Hold
Price Target: €130.00 → €135.00
Current: €136.30
Upside: -0.95%
Lonza Group AG
Dec 3, 2025
Maintained: Buy
Price Target: CHF 650.00
Current: CHF 567.80
Upside: +14.48%
Dec 3, 2025
Maintained: Buy
Price Target: $14 → $10
Current: $3.46
Upside: +189.02%
Dec 3, 2025
Maintained: Hold
Price Target: CHF 38.00 → CHF 50.00
Current: CHF 65.74
Upside: -23.94%
Apr 22, 2025
Maintained: Buy
Price Target: €300.00
Current: €243.40
Upside: n/a
Apr 22, 2025
Maintained: Buy
Price Target: €250.00
Current: €185.70
Upside: n/a
Mar 5, 2025
Maintained: Buy
Price Target: €715.00
Current: €750.50
Upside: n/a
Feb 12, 2025
Maintained: Hold
Price Target: 2,100p → 2,400p
Current: 1,561p
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: $14
Current: $1.96
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: €12.00
Current: €3.44
Upside: n/a
Jul 15, 2024
Maintained: Buy
Price Target: 912p
Current: 1,288p
Upside: n/a
May 15, 2024
Maintained: Hold
Price Target: €120.00
Current: €161.40
Upside: n/a
May 8, 2024
Maintained: Hold
Price Target: $37 → $40
Current: $81.15
Upside: n/a
Apr 3, 2024
Maintained: Sell
Price Target: CHF 4.00 → CHF 1.00
Current: CHF 5.90
Upside: n/a
Mar 25, 2024
Upgraded: Hold
Price Target: €0.88 → €105.00
Current: €235.60
Upside: n/a
Dec 29, 2023
Maintained: Hold
Price Target: $16
Current: $7.27
Upside: n/a
Nov 13, 2023
Maintained: Hold
Price Target: €11.50 → €11.00
Current: €10.68
Upside: n/a
Oct 4, 2023
Maintained: Hold
Price Target: $10
Current: $32.03
Upside: n/a